Compositions and methods for the treatment of depression

US11266627B1 · kind B1 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Mark Schmidt · Ekeren, BE
• Vanina Popova · Nijlen, BE
• Adam Savitz · Greenwich, US
• Rama Melkote · Jalan Pedongkelan, US
• Wayne C. Drevets · Titusville, US
• Srihari Gopal · Montgomery, US
• Darrel Pemberton · Zwaneven, BE
• Chakradhar Lagishetty · King of Prussia, US
• Iva Kezic · Ekeren, BE

Key dates

• Filing date: May 4, 2021
• Grant date: Mar 8, 2022
• Expiry date: May 4, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/24
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.